Actualités 42268.htm
InMed Pharmaceuticals Reports Full Year Fiscal 2024 Financial Results and Provides Business Update
Mon, 30 Sep 2024 05:17:00 GMT
Advances INM-901 program targeting several biological pathways associated with Alzheimer's diseaseFurther develops INM-089 demonstrating neuroprotection in the treatment of dry Age-related Macular ...
Ermenegildo Zegna Group Reports First Half 2024 Revenues of €960 Million With Profit at €31 Million and Adjusted EBIT at €81 Million
Wed, 18 Sep 2024 03:55:00 GMT
Revenues of €960.1 million, up 6% from H1 2023 (+8% at constant currency and -2.7% organic1 Profit of €31.3 million (3.3% profit margin) compared to €52.1 million in H1 2023 (5.8% profit margin) ...